3-溴-2-异丙氧基吡啶 | 717843-55-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-溴-2-异丙氧基吡啶
• 中文别名: 3-溴-2-异丙氧基吡啶,97+；2-异丙氧基-3-溴吡啶
• 英文名称: bromo-2-isopropoxypyridine
• 英文别名: 3-Bromo-2-isopropoxypyridine；3-bromo-2-propan-2-yloxypyridine
• CAS: 717843-55-5
• 化学式: C₈H₁₀BrNO
• 分子量: 216.077
• InChiKey: UHQQSDAMSSVOQU-UHFFFAOYSA-N

物化性质

• 沸点：
  222.9±20.0 °C(Predicted)
• 密度：
  1.383±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  、 3-溴-2-异丙氧基吡啶 在 palladium diacetate 、 三乙胺 、 三环己基膦 作用下， 以 甲苯 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family

  摘要：

  Inhibition of the sodium-coupled citrate transporter (NaCT or SLC13A5) has been proposed as a new therapeutic approach for prevention and treatment of metabolic diseases. In a previous report, we discovered dicarboxylate la (PF-06649298) which inhibits the transport of citrate in in vitro and in vivo settings via a specific interaction with NaCT. Herein, we report the optimization of this series leading to 4a (PF-06761281), a more potent inhibitor with suitable in vivo pharmacokinetic profile for assessment of in vivo pharmacodynamics. Compound 4a was used to demonstrate dose dependent inhibition of radioactive [C-14]citrate uptake in liver and kidney in vivo, resulting in modest reductions in plasma glucose concentrations.

  DOI：

  10.1021/acs.jmedchem.5b01752

文献信息

• Substituted pyridoindoles as serotonin agonists and antagonists
  申请人：——

  公开号：US20040186094A1

  公开（公告）日：2004-09-23

  The present invention is directed to certain novel compounds represented by structural Formula (I) 1 or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 5 , R 6 , R 7 , R 8 , R 9 , X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

  本发明涉及一些新型化合物，其结构式表示为（I）或其药用盐形式，其中R1、R5、R6、R7、R8、R9、X、b、k和n以及虚线在此处描述。本发明还涉及包含这些新型化合物作为活性成分的药物配方，以及这些新型化合物及其配方在治疗某些疾病中的用途。本发明的化合物是5-羟色胺激动剂和拮抗剂，在控制或预防包括肥胖、焦虑、抑郁症、精神病、精神分裂症、睡眠障碍、性功能障碍、偏头痛、头痛相关疾病、社交恐惧症以及胃肠道疾病（如胃肠道运动功能障碍）等中枢神经系统疾病中有用。
• Triphenylphosphine derivative, production process therefor, palladium complex thereof, and process for producing biaryl derivative
  申请人：——

  公开号：US20030065208A1

  公开（公告）日：2003-04-03

  Provided are a novel triphenyl phosphine derivative synthesized from a triphenylphosphine and a hydroxy-containing lactone; a palladium and a nickel complexes comprising the derivative as a ligand; and a process for preparing a biaryl derivative using the complex as a catalyst. A product can be easily separated from a catalyst or a phosphorus compound, and biaryl derivative can be synthesized in a higher yield, by using the complex of the present invention as a catalyst.

  提供了一种新型的三苯基膦衍生物，通过三苯基膦和含羟基的内酯合成；一种以该衍生物为配体的钯和镍配合物；以及一种利用该配合物作为催化剂制备联苯衍生物的方法。通过使用本发明的复合物作为催化剂，产品可以很容易地与催化剂或磷化合物分离，联苯衍生物可以以更高的产率合成。
• Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
  申请人：——

  公开号：US20040180875A1

  公开（公告）日：2004-09-16

  The present invention is directed to novel compounds represented by structural Formula (I): 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , R 4a , R 5 , R 6 , R 7 , R 8 , R 9 , and m, are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain central nervous system disorders. The compounds of this invention are serotonin receptor modulators, in particular 5HT 2C receptor agonists and antagonists, and are useful in the control or prevention of central nervous system disorders including obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, and sexual disorders.

  本发明涉及由结构式(I)表示的新化合物或其药学上可接受的盐，其中R1、R4a、R5、R6、R7、R8、R9和m在此被定义。本发明还涉及包含这些新化合物作为活性成分的制药配方以及在治疗某些中枢神经系统疾病中使用这些新化合物和它们的配方。本发明的化合物是血清素受体调节剂，特别是5HT2C受体激动剂和拮抗剂，并且在控制或预防中枢神经系统疾病，包括肥胖症、厌食症、暴食症、抑郁症、焦虑症、精神病、精神分裂症、偏头痛、成瘾行为、强迫症和性功能障碍方面是有用的。
• TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE
  申请人：Mitsubishi Rayon Co., Ltd.

  公开号：EP1270582A1

  公开（公告）日：2003-01-02

  Provided are a novel triphenyl phosphine derivative synthesized from a triphenylphosphine and a hydroxy-containing lactone; a palladium and a nickel complexes comprising the derivative as a ligand; and a process for preparing a biaryl derivative using the complex as a catalyst. A product can be easily separated from a catalyst or a phosphorus compound, and biaryl derivative can be synthesized in a higher yield, by using the complex of the present invention as a catalyst.

  本发明提供了一种由三苯基膦和含羟基内酯合成的新型三苯基膦衍生物；一种以该衍生物为配体的钯和镍配合物；以及一种以该配合物为催化剂制备双芳基衍生物的工艺。使用本发明的配合物作为催化剂，产物可以很容易地从催化剂或磷化合物中分离出来，并且可以以更高的产率合成双芳基衍生物。
• TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES
  申请人：MITSUBISHI RAYON CO., LTD.

  公开号：EP1270582B1

  公开（公告）日：2006-08-30